Cellution Biologics Inc. (“Cellution Biologics” or the “Company”), a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, announces the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix (ADM) business from Elutia Inc. (Nasdaq: ELUT). The acquisition marks Cellution Biologics’ entry into the U.S. reconstructive surgery market, adding a new surgical category to its existing portfolio across wound care, ocular repair and other surgical applications. SimpliDerm is an established human acellular dermal matrix with a proven commercial presence in the U.S. reconstructive surgery market.
Read the full article: Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc. //
Source: https://www.globenewswire.com/news-release/2026/08/18/3347103/0/en/cellution-biologics-completes-acquisition-of-simpliderm-from-elutia-inc.html